References in periodicals archive ?
With this IND having been submitted, Valera said it is now preparing for a Phase I/II, open label study of its naltrexone implant in healthy volunteers with a history of opioid abuse.
ETHOS II is a three-center, open label study during which patients will receive a novel formulation of estradiol with reduced polymer load.
Anderson Cancer Center entitled: "An Open Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients with Advanced Cancer" which was begun in March, 2005, originally was designed to assess Atiprimod's activity in solid tumors and hematologic malignancies.

Full browser ?